In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.

• Track 2-1: Innovative & Structure Based Strategies
• Track 2-2: Requirement to Determine the Active Principle
• Track 2-3: Bioequivalence Criteria
• Track 2-4: Pharmacogenomics
• Track 2-5: Advanced Oral Drug Delivery Technologies
• Track 2-6: BA of Contaminants in Soils & Sediments

The bio similar segment is one of the fastest growing segments and is likely to reach more than USD 25 billion by 2020.  Despite high development costs, the bio similar segment is likely to witness rapid growth due to the rising number of off-patent biologic drugs. The growth of this sector is attributed to the positive outcomes of on-going clinical trials and the growing demand for bio similar in different therapeutic applications. The application of advanced technologies such as recombinant DNA technology, genetic engineering, and combinatorial chemistry has increased the entry of novel biopharmaceuticals in the market which will contribute to this segment’s growth over the next four years.

• Track 3-1: Cancer Therapeutics
• Track 3-2: Cardiovascular Therapeutics
• Track 3-3: Diabetes Therapeutics
• Track 3-4: Adverse Drug Reactions with Pharmaceutical Products
• Track 3-5: Bioanalytical Approaches

Drug Metabolism conference is a platform to have all the scientific eminent across the globe. Drug metabolism is the term used to describe the biotransformation of pharmaceutical substances in the body so that they can be eliminated more easily. The metabolites of some drugs are pharmacologically active and exert an effect on the body. The active metabolite of some medications is responsible for the principal action of the drug. In this case, the drug formulation is referred to as a pro drug (some chemical substances which do not produce pharmacological effects until they are chemically altered within the body). The rate of drug metabolism affects the efficacy and toxicity of the drug for patients who have very high or low metabolism rates.

• Track 4-1: Drug Discovery: Tools and Techniques
• Track 4-2: Phase I vs. Phase II Metabolism
• Track 4-3: Bioequivalence analysis of highly variable drugs
• Track 4-4: Drug Efficacy and Toxicity
• Track 4-5: Genetics in Drug Development
• Track 4-6: Bioavailability Study for cancer drugs

Bioavailability is one of the essential tools in Pharmacokinetics, as bioavailability must be considered when calculating dosages for no intravenous routes of administration. An appropriate BE method often needs to be established based on a scientific analysis of each drug product. The above was a brief overview of bioavailability study protocol with some of its specification and essential features. Bioavailability or Bioequivalence which is actually the heart and soul of therapeutic response of a drug moiety in a given drug product.

• Track 5-1: Bioavailability Metrics
• Track 5-2: Marine Natural Products
• Track 5-3: Bioequivalence Cardiovascular Products
• Track 5-4: Drug Metabolism / Biotransformation
• Track 5-5: Physico-chemical Factors

Human pharmacokinetic in vivo studies are often presumed to serve as the “gold standard” to assess product bioequivalence (BE) of immediate-release (IR) solid oral dosage forms. However, when this general assumption is re-visited, it appears that in vitro studies are sometimes better than in vivo studies in assessing BE of IR solid oral dosage forms. Reduced costs are achieved through avoiding in vivo studies where BE is self-evident, where biopharmaceutical data anticipates BE, and where in vivo BE study type II error is high. Sponsors of potential in vivo human pharmacokinetic BE testing should be required to justify why in vitro data is insufficient, similar to proposed animal testing requires justification to not employ an in vitro approach.

• Track 6-1: Bioinformatics: Computer-aided Drug Design
• Track 6-2: Bioequivalence Protocols: In vitro-In vivo correlation
• Track 6-3: Pre-clinical research/trail
• Track 6-4: In vitro and In Vivo drug product research
• Track 6-5: Human Clinical Trial Phases
• Track 6-6: Oral bioavailability: In vitro and in vivo evaluation

Drug product performance is a vital aspect of drug development as it draws on interdisciplinary expertise from both pharmaceutics and pharmacokinetics disciplines. It is at the key interface that the discipline of bio pharmaceutics has emerged. The past two decades have witnessed considerable advances in bio pharmaceutics particularly with regard to bioavailability and bioequivalence, as they relate to product quality and regulatory standards of approval.

• Track 7-1: Basic concepts of bio pharmaceutics
• Track 7-2: Role of bio pharmaceutics in various stages of drug development
• Track 7-3: Pharmacy Practices and its Challenges
• Track 7-4: Pre-clinical & Clinical Formulation studies
• Track 7-5: Identification & Validation of biological targets

 Pharmaceuticals Formulation conference is a platform to have all the scientific eminent across the globe. Drug product formulation is at the core of Particle Sciences. Industry-wide, delivery of active pharmaceutical ingredients (APIs) has taken center stage along with the API's themselves. Focused initially on problematic new chemical entities (NCEs), delivery systems are now the go-to approach for both NCE commercialization and the refinement and repurposing of existing APIs. The biological and chemical needs generally fall into one or a combination of a small number of categories. In addition to physicochemical and physiologic goals, business concerns also drive the use of sophisticated drug delivery systems. Intellectual property, life-cycle management, cost and market differentiations are examples.

• Track 8-1: Bioequivalence PreClinical trials and Clinical Endpoint Studies
• Track 8-2: Solid, Topical & Parenteral Dosage Form
• Track 8-3: Investigation of New Drugs
• Track 8-4: Immediate & Modified : Release Products
• Track 8-5: Analysis of BA/BE by Oral vs Parental

Pharmacodynamics and pharmacokinetics conference is a platform to have all the scientific eminent across the globe. Pharmacodynamics and pharmacokinetics are the two principal areas of pharmacology. Pharmacodynamics is the study of the molecular, biochemical, and physiological effects of drugs on cellular systems and their mechanisms of action. Pharmacokinetics focuses rather on how the body affects the drug, in terms of its absorption, metabolism, distribution and elimination. Today, pharmacologists use a variety of techniques, including genetics, molecular biology and chemistry, to explain and manipulate the pharmacological action of substances for health purposes. BA and BE frequently rely on pharmacokinetic measures such AUC to assess extent of systemic exposure and C_max and T_max to assess rate of systemic absorption. It has a broad scope, from the discovery of new target molecules, to the effects of drug usage in whole populations. Bioanalytical method techniques and validation plays a vital role in the evaluation and interpretation of bioequivalence, pharmacokinetics, and toxicokinetic studies. Clinical and experimental pharmacology deals with Clinical drug developments & therapeutics. Pharmacogenomics is the study of how genetic variation influences responses to drugs. This includes how genetic variants affect drug metabolism, efficacy and toxicity, with the goal of improving and personalizing drug therapy.

• Track 9-1: Clinical research phase studies
• Track 9-2: Pharmacokinetics & Pharmacodynamics
• Track 9-3: Drug Safety and Efficacy
• Track 9-4: Posology & Development
• Track 9-5: Drug-release studies

Biowaivers conference  is a platform to have all the scientific eminent across the globe. Biowaivers are generally provided for multiple strengths after approval of a bioequivalence study. Biowaiver is applied to a regulatory approval process when the application (dossier) is approved based on evidence of equivalence other than an invivo bioequivalence test. For solid oral dosage forms, the evidence of equivalence is determined based on an invitro dissolution profile comparison between the multisource and the comparator product. The objective of this work was to suggest the biowaivers potential of biopharmaceutical classification system which are known to increase the solubility, dissolution, oral absorption of water insoluble drugs.

• Track 10-1: Waivers of Pharmaceutical Dosage Form
• Track 10-2: Waiver for In vivo Bioavailability or Bioequivalence
• Track 10-3: BCS biowaivers
• Track 10-4: In Vitro PreClinical ADME/BCS Testing
• Track 10-5: Dissolution Testing in Drug Formulation

Drug discovery process basically is a patient oriented science, where researchers strive to improve the existing drugs or invent a totally new chemical entity, which should be ideally more potent than any existing drug of a similar category. If not, then at least it should be safer than those existing. This process is a very time consuming and expensive activity, calling for the expertise of many eminent researchers. It takes nearly 12-14 years of exhaustive research and a huge amount of financial investment for the discovery of a single drug

• Track 11-1: Nursing and Surgical Instrumentation
• Track 11-2: Occupational Health and Nutrition
• Track 11-3: Mental, Oral and Healthcare Management
• Track 11-4: Vitamins &Minerals Bioavailability- Micro and Macro
• Track 11-5: Food/Herbal Remedies- Drug Interaction

Failure at any stage would mean a huge loss for the company. Hence, a lot of planning is required even before the project is underway. Recently, with the use of technology the process is becoming a less risky business, because of the ability of the computers to predict the possible outcomes. This will surely reduce the efforts in fruitless directions. Hence, the most important and most common biological targets for drug discovery are either enzymes regulating the biochemistry or the receptors through which many hormones and endogenous effectors show their response.

• Track 12-1: Design and Statistical evaluation of BA/BE studies
• Track 12-2: WHO Approaches
• Track 12-3: FDA Approach and regulations
• Track 12-4: TGA and risk management approach
• Track 12-5: European Guidelines

Entrepreneur Meet is a platform to bring all the eminent speakers and researchers together in this conference  The decision to terminate a trial early due to unacceptable toxicity or substantial and convincing evidence of benefit is complex and must account for many factors These include possible imbalances in risk factors between treatment groups, whether the patients have the risk profile assumed in the design, patient compliance to therapy, quality and timeliness of data, possible sources of bias, consistency of primary and secondary outcome variables, the benefit-to-risk ratio, consistency of results with external data, and the impact of early termination on the medical community as well as the public. Evaluation of these issues goes beyond routine statistical tests and requires the collective judgment of experts, such as those represented by a DSMB. For decades the creation of new medicines has increased quality and quantity of life for patients around the globe.

• Track 13-1: Issues in the design and analysis of clinical trials
• Track 13-2: Clinical toxicology
• Track 13-3: Novel excipients : need and opportunity
• Track 13-4: Expanding market: Investors and consumers.